IL17F
Interleukin-17F
As of the edition of 20 October 2026, IL17F (interleukin-17F, UniProt Q96PD4) has 2 drugs tested at it and 4 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q96PD4
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 9
- Disease areas
- Skin and connective tissue; Bones, joints and muscles; Infections; Immune system; Heart and blood vessels; Inherited and neonatal; Injuries; Lungs and airways
- Registered trials of its drugs
- 67
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Bimekizumab | Marketed | Phase 4 | Ends 2035 |
| M-1095 | Active | Phase 3 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 3 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| UCB | Route B |
The other 3 companies at IL17F
In the product4 companies in all; 3 are not named here, and no score is.
See the 4 companies at IL17F, ranked, with the facts behind eachRequest access. Nothing is shown until you do.